Medeor Therapeutics
Medeor Therapeutics Receives FDA Clearance of IND Application and Special Protocol Assessment for Pivotal Clinical Study of MDR-101
28 avr. 2017 07h30 HE | Medeor Therapeutics
Personalized cellular immunotherapy designed to prevent transplant kidney rejection and eliminate the need for chronic anti-rejection drugs Single Phase 3 study will evaluate functional immune...